ACORN CAPITAL ADVISORS, LLC: 13F holdings
CIK 20544102026Q2
| Positions | 20 |
|---|
| Reported value | $366.5m |
|---|
| Filed | 2026-08-14 |
|---|
Change since last quarter
| Positions | 20 (-2 vs prior quarter) |
|---|
| Reported value | $366.5m (+4.2%) |
|---|
Top 10 holdings
| Security | Shares | Value | Weight |
|---|
| CGON CG ONCOLOGY INC | 1,131,500 | $80.4m | 21.9% |
| UROGEN PHARMA LTD | 1,673,420 | $61.6m | 16.8% |
| TRVI TREVI THERAPEUTICS INC | 2,144,844 | $40.0m | 10.9% |
| CANDEL THERAPEUTICS INC | 3,497,948 | $36.0m | 9.8% |
| PBYI PUMA BIOTECHNOLOGY INC | 4,131,299 | $33.5m | 9.1% |
| JBIO JADE BIOSCEINCES INC | 986,760 | $21.9m | 6.0% |
| BCAX BICARA THERAPEUTICS | 643,381 | $19.1m | 5.2% |
| KARYOPHARM THERAPEUTICS INC | 1,518,113 | $14.8m | 4.0% |
| ONKURE THERAPEUTICS INC | 2,839,674 | $12.9m | 3.5% |
| HELUS PHARMA INC. | 1,540,266 | $10.2m | 2.8% |
Get the full book
import finzdata as yf
yf.Client().manager_holdings(cik="2054410")
Every position, quarter by quarter since 2013, with adds, trims and exits, on the look-back bundles.
Get a free API keySee history bundlesDownload free samples